Dr. Richard Gliklich is the CEO of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.

Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices.

Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.

Robin Pepper is the Chief Business Officer and Vice President of Business Operations at OM1, Inc. Prior to joining OM1, Robin was the Global Head of Clinical and Data Operations at Quintiles where she oversaw more than 350 employees across a variety of operational groups in the Americas, Europe and Asia-Pacific.

Previously, she was the Vice President of Professional Services at Outcome Sciences, Inc. and a consultant at Accenture. She received an MBA from the Wharton School at the University of Pennsylvania and a BA from Davidson College.

Dr. Vandana Menon is the Vice President of Research at OM1, Inc. Prior to working at OM1, Vandana held leadership positions in the life sciences industry heading global Health Economics and Outcomes Research teams at Baxalta Inc. and Cubist Pharmaceuticals Inc. She has extensive consulting experience serving as scientific lead for numerous real-world and late phase research projects at Outcome and Quintiles.

Vandana is trained as a clinical researcher with a medical degree from Stanley Medical College, India, a Ph.D. from the Univ. of Tennessee, Memphis, and an MPH from the Harvard School of Public Health. Prior to moving to industry, she spent 9 years on faculty in the Division of Nephrology at Tufts Medical Center and currently serves as Adjunct Faculty in the Institute for Clinical Research and Health Policy Studies at Tufts.

For fun, she loves hiking and biking with her family and watching football: Go Pats!

Costas Boussios, PhD is Vice President of Data Science at OM1, where he leads research and development of OM1's Machine Learning solutions. Prior to OM1, Dr. Boussios was the Chief Data Scientist at Mitra Capital LLC, the top performing equity market neutral fund of 2015. He has also led Data Science at Cignifi Inc, where he developed credit scoring solutions using mobile telephony data for millions of unbanked consumers in developing countries, and at Zakipoint Health LLC, where he developed patent-pending technology in optimization of health goal program engagement and adherence. He has also held the position of Director of Analytics at D&B working on commercial credit and insolvency risk scoring. Dr. Boussios holds a PhD from Mechanical Engineering at MIT with specialization in Machine Learning and Feedback Control Systems.

Philip Wickline is the Chief Technology Officer at OM1, Inc. Prior to joining OM1, Philip was an Executive in Residence at Matrix Partners, founder and CEO of intelligent marketing platform Zaius, Chief Technology Officer of Big Data analytics provider Hadapt, and Vice President of Engineering and Chief Architect of analytics and search platform Endeca.

Philip received his M.S. in Computer Science degree from Carnegie Mellon and a B.A. with High Honors from Wesleyan University.

Andy DeMayo is Senior Counsel and Head of Strategic Partnerships at OM1, Inc. In this role, he is responsible for handling a wide range of legal issues, including those related to contracting and data privacy. Prior to joining OM1, he served as Senior Director in the Office of General Counsel at Quintiles, a global provider of product development and integrated healthcare services. In this role, he drafted and negotiated complex commercial contracts with biopharmaceutical companies, healthcare organizations, research sites, consultants and government agencies; and assisted with Quintiles’ trademark portfolio.

In previous roles, he worked as Senior Corporate Counsel for Outcome Sciences, Inc., In-House Counsel and Compliance Officer for Pioneer Behavioral Health (PHC, Inc.), and Corporate Counsel for Med Diversified Inc. Andy was a chapter co-author, contributor, and reviewer of the Agency for Healthcare Research and Quality handbook, “Registries for Evaluating Patient Outcomes: A User’s Guide,” and he co-authored a chapter in the Health Law & Compliance Update (2013 Edition).

Andy is a graduate of Boston College Law School and earned his bachelor’s degree from Tufts University. Outside of the office, he enjoys golfing, collecting vinyl records, and spending time with his family.

As the Head of Marketing at OM1, Inc, Renee Hurley oversees strategy and implementation of the marketing, communications, and thought-leadership programs. Prior to joining OM1, Renee led the global marketing strategies, initiatives and teams for Quintiles Integrated Healthcare Services (IHS), which included Real-World & Late Phase Research, Commercial, Health Engagement & Communications, Advisory Services, and Payer & Provider business units.

In previous roles, Renee oversaw real-world research and provider marketing, communications and thought-leadership for Outcome Sciences Inc., worked in a variety of marketing roles for primary care and specialty conferences at MC Communications, and was a media researcher at MediaMap. She is an alumni of Boston University and enjoys exploring the world and hiking with her family.

Tom Engel is the Vice President of Business Development for OM1, Inc. Previously, Tom led the US Sales Team for QuintilesIMS Real World Evidence following the merger of Quintiles and IMS Health. Prior to the merger, Tom led the North America Sales Team for Real World and Late Phase Research at Quintiles (NYSE: Q), the world's largest Clinical Research Organization (CRO). In 2004, Tom joined Rich Gliklich at Outcome Sciences, Inc. (Outcome) where he focused on sales and market development through the 2011 acquisition of Outcome by Quintiles.

In 1998, Tom joined Phase Forward (later acquired by Oracle) as the first Product Manager for InForm, the market-leading electronic data capture system for clinical development. He joined IntraLinks, Inc. in 2002 as Vice President of Strategic Business Development tasked to develop new sales channels for IntraLinks’ clinical products.

Tom received his Bachelor of Arts degree from Boston College in Mathematics a very long time ago. When not at home with his family, Tom can be found walking in the woods or on the nearest mountain.

Dan Levy is the Vice President of Data Solutions at OM1, Inc. In his role, Dan is responsible for developing and managing the partner ecosystem, with a focus on creating data solutions that generate value to both OM1 customers and partners.

For the prior 4 years, Dan was Chief Technology Officer at Amazing Charts, an ambulatory electronic medical record and health IT company. Dan led the software engineering, quality assurance, cloud operations, and data & analytics functions, and helped lead the company through an acquisition to Harris Healthcare. For the 8 years prior, Dan served as Vice President of Engineering and later as Chief Technology Officer at Outcome Sciences, a division of Quintiles, focusing on real-world and late phase research.  Prior to that, Dan held a number of technical leadership roles in both public and private, venture backed companies.

Dan received a BA in General Science from Brandeis University and an MS in Software Engineering from Boston University.